NCT05573477View on ClinicalTrials.gov

Evaluation of Efficacy and Safety of ATB-1011+ATB-1012 Co-administration for Essential Hypertension and Type II Diabetes

PHASE3UnknownINTERVENTIONAL
Enrollment

248

Participants

Timeline

Start Date

November 16, 2022

Primary Completion Date

January 31, 2024

Study Completion Date

June 30, 2024

Conditions
Essential HypertensionDiabetes Mellitus, Type 2
Interventions
DRUG

ATB-1011

Oral tablet

DRUG

ATB-1012

Oral tablet

DRUG

ATB-1013

Oral tablet

DRUG

ATB-1011 placebo

Placebo matched to ATB-1011

DRUG

ATB-1012 placebo

Placebo matched to ATB-1012

DRUG

ATB-1013 placebo

Placebo matched to ATB-1013

Trial Locations (1)

13620

RECRUITING

Seoul National University Bundang Hospital, Seongnam-si

Sponsors

Lead Sponsor

Autotelicbio
All Listed Sponsors
lead

Autotelicbio

INDUSTRY

NCT05573477 - Evaluation of Efficacy and Safety of ATB-1011+ATB-1012 Co-administration for Essential Hypertension and Type II Diabetes | Biotech Hunter | Biotech Hunter